All In Biotech

Drug Trial Radar · NCT02571192

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: May 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Oct 1, 2015

Primary completion

Oct 1, 2015

Study completion Oct 1, 2015

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.

Conditions

  • Non-Alcoholic Steatohepatitis

Interventions

  • SHP626Drug

    single oral dose 50mg SHP626 with approximately 5.95 μCi RAD

  • 5.95 μCi RADRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameters will be determined from the plasma and blood concentration time data of total radioactivity and from the plasma concentration-time data for SHP626 by non-compartmental analysis.Time frame: Day 1 to day 10
  2. Total radioactivity (RAD) in whole blood and plasmaTime frame: Day 1 to day 10
  3. To determine the total RAD in urine and feces.Time frame: Day 1 to day 10
  4. Maximum plasma concentration (Cmax) of 50mg [14C]-SHP626 and RAD occurring at time of maximum observed concentration (tmax)Time frame: Day 1 to day 10
  5. Area under the plasma concentration curve (AUC0-t) of 50mg [14C]-SHP626 and RAD from the time of dosing to the last measurable concentrationTime frame: Day 1 to Day 10
  6. Area under the plasma concentration curve (AUC0-∞ ) of 50mg [14C]-SHP626 and RAD extrapolated to infinity, calculated using the observed value of the last non-zero plasma concentrationTime frame: Day 1 to Day 10
  7. First order rate constant associated with the terminal portion of the plasma curve terminal half-life (t½) for 50mg [14C]-SHP626 and RADTime frame: Day 1 to Day 10
  8. Total body clearance (CL/F ) of 50mg [14C]-SHP626 and RAD for extravascular administration divided by the fraction of dose absorbedTime frame: Day 1-10
  9. Volume of distribution (Vz/F ) of 50mg [14C]-SHP626 and RAD associated with the terminal slope following extra-vascular administration divided by the fraction of dose absorbedTime frame: Day 1-10
  10. Cumulative amount (Aef )of RAD recovered in stool over the dosing intervalTime frame: Day 1-10
  11. Excreted Percent of RAD recovered in stool over the dosing intervalTime frame: Day 1-10
  12. Cumulative amount (Aeu ) of RAD recovered in urine over the dosing intervalTime frame: Day 1-10
  13. Excreted Percent of RAD recovered in urine over the dosing intervalTime frame: Day 1-10
  14. Renal Clearance (CLR ) of 50mg [14C]-SHP626Time frame: Day 1 -10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Madison Clinical Research Unit

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.